Drug Trial Radar · NCT07594106
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
265
Planned (sponsor's estimate)
Start
Jul 20, 2026
Primary completion
Oct 27, 2030
Study completion Oct 27, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for: * Any side effects of study drugs * How well the study drugs work * How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times * If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected * What is the best dose of REGN15505 when administered alone and with cemiplimab and the best dose of REGN15505 and REGN4336 when used in combination
Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN15505Drug
Administered per protocol
REGN15505+CemiplimabDrug
Administered per protocol
REGN15505+REGN4336Drug
Administered per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to 5 years
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
- Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 5 years
- Occurrence of Adverse Events of Special Interest (AESIs)Time frame: Up to 5 years
- Composite Response (CompR) based on ≥50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic assessment of complete response (CR) or partial response (PR)Time frame: Up to 5 years
- Objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to 5 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Phoenix
Goodyear, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
H. Lee Moffitt Cancer Center
Tampa, Florida · Recruiting
City of Hope Chicago, City of Hope Cancer Center Chicago
Zion, Illinois · Recruiting
Washington University
St Louis, Missouri · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.